InvestorsHub Logo
Followers 48
Posts 12063
Boards Moderated 0
Alias Born 09/12/2017

Re: moneycrew post# 218376

Friday, 03/10/2023 12:55:10 AM

Friday, March 10, 2023 12:55:10 AM

Post# of 233566
Wheres the primary endpoint data?

CytoDyn plans to publish soon the safety and efficacy data in which it met its primary endpoint, in its Phase 2b/3 randomized, double-blinded, placebo-controlled trial for the HIV-MDR population, in a peer-reviewed journal.
https://www.sec.gov/Archives/edgar/data/1175680/000155837022015602/cydy-20221028xex99d1.htm



Cyrus said the primary endpoints were met right?

RIGHT?

Cyrus Arman, Ph.D., President of CytoDyn, stated, "We have decided to voluntarily withdraw our BLA for the HIV-MDR population at this time only after extensive review and deliberation, including audits from three external independent regulatory quality firms. While the Company met its primary endpoints in these pivotal trials
https://www.sec.gov/Archives/edgar/data/1175680/000155837022015602/cydy-20221028xex99d1.htm

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News